Genital Herpes Treatment Market

Comments

Transcription

Genital Herpes Treatment Market
Genital Herpes
Treatment Market
Share, Global Trends,
Analysis, Research, Report,
Opportunities,
Segmentation and Forecast,
2016-2026
Future Market Insights
www.futuremarketinsights.com
[email protected]
Future Market Insights (FMI) is a premier provider of syndicated research reports, custom research reports, and consulting
services. We deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes,
technology inputs, valuable growth insights, aerial view of the competitive framework, and future market trends.
We provide research services at a global as well as regional level; key regions include GCC, ASEAN, and BRIC.
Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and
Retail.
We have a global presence with delivery centers across India specializing in providing global research reports and country
research reports. FMI is headquartered out of London, U.K., with a state-of-the-art delivery center located in Pune, India.
We combine our knowledge and learning from every corner of the world to distill it to one thing – the perfect solution for
our client.
Research Capabilities
Sector Coverage








Customized Research
Syndicated Research
Investment Research
Social Media Research
Automotive and Transportation
Electronics, Semiconductor, and ICT
Retail and Consumer Products
Industrial Automation and Equipment
Customized
Research
Subscription Information
Syndicated
Research
For detailed subscription information please contact
Investment
Research
T: +44 (0) 20 7692 8790 | D: +44 20 3287 4268
Social Media
Research
Hari. T (Sr. Manager - Global Business Development)
Email: [email protected]




Chemicals & Materials
Food and Beverages
Services and Utilities
Energy, Mining, Oil, and Gas
Report
Description
Report Description
General herpes is a sexually transmitted infection (STI), caused by herpes simplex virus. It
causes painful blisters on the genital organs and surrounding areas of both men and women.
It also affects mucus membrane present in the body. Prevalence rate of genital herpes is high
in women when compared with men. Genital herpes is a chronic condition and it is not
having any cure, however, medication is available to reduce triggered symptoms of the
disease. The viral infection is permanent in human body and will become active and causes
painful blisters occasionally in first two years. The average rate of recurrence is five times in a
first two years and the rate of recurrence will decrease in each time. Prevalence rate of this
disease is high in population with age from 20 to 24 years. It also causes severe health
problems in a pregnant women.
Treatment methods include initial treatment, intermittent treatment and suppressive
treatment. Antiviral drugs are usually prescribed for seven to ten days in the initial treatment.
In an intermittent therapy, treatment was prescribed depend on the symptoms patient such
as cold sores. In a suppressive therapy, based on the symptoms patients has to take
medication every day. Drugs include acyclovir, famciclovir, and Val acyclovir are prescribed for
genital herpes therapy and based on the condition drugs are given to patient orally and
intravenously.
Request Free Report [email protected] http://www.futuremarketinsights.com/reports/sample/repgb-1390
Genital Herpes Treatment Market: Drivers and Restraints
According to center for disease control and prevention approximately 50 million population
Report
Description
Report Description
affected with genital herpes in the U.S. Raising prevalence rate of herpes simplex virus,
insecure sexual contacts are the major factors deriving the growth of genital herpes
treatment market. Moreover, increasing awareness about sexually transmitted diseases and
raising awareness about healthcare drives the genital herpes treatment market.
Genital Herpes Treatment Market: Segmentation
Genital Herpes Treatment Market is segmented into product type, distribution channel and
region
Based on genital herpes product type, the global genital herpes treatment market is
segmented into:
•Acyclovir
•Famciclovir
•Valacyclovir
Based on genital herpes treatment distribution channel, the global genital herpes treatment
market is segmented into:
•Hospital Pharmacies
•General Pharmacies
•Drug stores
Report
Description
Report Description
Genital Herpes Treatment Market: Overview
Increasing healthcare awareness among mass population along with rise in prevalence rate
of genital herpes is expected to propel the overall demand for Genital Herpes Treatment
worldwide. The market is expected to witness a healthy growth over the forecast period
(2016-2026)
Genital Herpes Treatment Market: Region- wise Outlook
Depending on geographic regions, the global genital herpes treatment market is segmented
into seven key regions: North America, Latin America, Eastern Europe, Western Europe, and
Asia Pacific excluding Japan, Japan and Middle East & Africa. North America is expected to be
the most dominant region for genital herpes treatment during the forecast period, owing
strong healthcare setup and people having good awareness about STI diseases. However,
Asia Pacific region is expected to expand at remarkable CAGR in genital herpes treatment
market due to increasing healthcare awareness and favorable policies implemented by the
government to start-up companies.
Visit For [email protected] http://www.futuremarketinsights.com/toc/rep-gb-1390
Genital Herpes Treatment Market: Key Players
Some of the key players in this market are Teva Pharmaceuticals Inc., GlaxoSmithKline,
Ranbaxy Laboratories Ltd., Mylan Pharmaceuticals Inc., Hospira Inc., Apotheca Inc., Novartis
AG, Novopharm Ltd., Dr Reddys Laboratories Ltd., Sandoz Inc. and others.
Thank You!
To know more about us, please visit our website:
www.futuremarketinsights.com
For sales queries or new topics email us on:
[email protected]
Future Market Insights: 616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
T: +1-347-918-3531 | D: +1-845-579-5705

Similar documents